Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 9/20 | 0.76 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.64 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | CHUK | O15111 | 1/20 | 0.60 |
| ▸ | PLK1 | P53350 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518539 | 0.88 | IKBKB (0.70) | IKBKBPIK3CAPIK3CBPIK3CGKMT2A | |
| SCHEMBL3520003 | 0.88 | IKBKB (0.69) | IKBKBPIK3CAPIK3CBPIK3CGKMT2A | |
| SCHEMBL3518431 | 0.86 | IKBKB (1.00) | IKBKBCDK2MAPK8MAPK10 | |
| SCHEMBL3521505 | 0.86 | KDM4E (0.66) | IKBKBPIK3CAPIK3CBPIK3CGKMT2A | |
| SCHEMBL3521763 | 0.83 | IKBKB (0.76) | IKBKBCHUKCDK2MAPK8MAPK10 | |
| SCHEMBL4028080 | 0.82 | IKBKB (0.74) | IKBKBPIK3CAPIK3CBPIK3CGKMT2A | |
| SCHEMBL3521184 | 0.80 | IKBKB (1.00) | IKBKBCDK2ABL1 | |
| SCHEMBL3518295 | 0.79 | IKBKB (0.76) | IKBKBCHUKMAPK8MAPK10 | |
| SCHEMBL3516849 | 0.79 | IKBKB (0.68) | IKBKBCHUKCDK2MAPK8MAPK10 | |
| SCHEMBL2564566 | 0.78 | CA1 (0.61) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | claimed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | claimed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079543-A1 | Anilino-pyrimidine analogs | DPYD, TYMP, ADORA3 | IKBKB 3246/4885PIK3CA 506/4885PIK3CB 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.